Neural Therapeutics Inc. ( (TSE:NURL) ) just unveiled an announcement.
Neural Therapeutics Inc. has submitted a renewal application to the Peruvian agency SERFOR to continue its analysis of previously collected cactus samples, which are crucial for their research on mental illness treatments. The company has also extended its letter of intent with Hanf.com, aiming to finalize a definitive agreement by the end of May 2025, indicating ongoing strategic partnerships and research advancements.
More about Neural Therapeutics Inc.
Neural Therapeutics Inc. is an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders.
Average Trading Volume: 85,804
For an in-depth examination of NURL stock, go to TipRanks’ Stock Analysis page.